{"id":33410,"date":"2018-02-09T11:35:24","date_gmt":"2018-02-09T11:35:24","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=33410"},"modified":"2018-07-21T11:43:55","modified_gmt":"2018-07-21T11:43:55","slug":"us-darunavir-label-updated-drug-interactions-and-pregnancy","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/33410","title":{"rendered":"US darunavir label updated: drug interactions and pregnancy"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Recent updates to the full prescribing information for darunavir includes changes linked to drug interactions and use in pregnancy. [1, 2]<\/strong><\/p>\n<p>Table 11 include new information about anticonvulsants, antifungals, antipsychotics, narcotic analgesics metabolized by CYP3A, and platelet aggregation inhibitor as follows:<\/p>\n<ul>\n<li>Clonazepam. Clinical monitoring of anticonvulsants that are metabolised by CYP3A is recommended<\/li>\n<li>Perphenazine. A decrease in the dose of antipsychotics that are metabolised by CYP3A or CYP2D6 may be needed when co-administered with darunavir\/ritonavir.<\/li>\n<li>Narcotic analgesics metabolised by CYP3A: e.g. fentanyl, oxycodone. Careful monitoring of therapeutic effects and adverse reactions associated with CYP3A-metabolised narcotic analgesics (including potentially fatal respiratory depression) is recommended with co-administration.<\/li>\n<li>Tramadol. A dose decrease may be needed for tramadol with concomitant use.<\/li>\n<li>Platelet aggregation inhibitor ticagrelor. Co administration of darunavir\/ritonavir and ticagrelor is not recommended.<\/li>\n<\/ul>\n<p>The section on use in pregnancy includes a pharmacology study in 35 HIV positive pregnant women comparing once-daily and twice-daily dosing. Results included lower drug exposure during the third trimester, especially in the once-daily arm. All 29 infants with available results were HIV negative at delivery or 16 weeks postpartum.<\/p>\n<p>Please see full prescribing information for full details.<\/p>\n<p>References<\/p>\n<ol>\n<li>US FDA HIV email update. Darunavir (Prezista) label revised. (30 January 2018).<\/li>\n<li>US FDA HIV email update. Darunavir\/cobicistat (Prezcobix) label revised. (30 January 2018).<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Recent updates to the full prescribing information for darunavir includes changes linked to drug interactions and use in pregnancy. [1, 2] Table 11 include new information about anticonvulsants, antifungals, antipsychotics, narcotic analgesics metabolized by CYP3A, and &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-33410","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/33410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=33410"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/33410\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=33410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=33410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=33410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}